Children's Hospital Colorado
Peter Chase, MD

Peter Chase, MD

Specialties:
Endocrinology - Pediatric
Conditions:
Juvenile Diabetes
specialties:

Endocrinology - Pediatric

conditions:

Juvenile Diabetes

Get to know his background

Undergraduate 1958

University of Wisconsin System (WI)

Medical School 1961

University of Wisconsin School of Medicine and Public Health

Residency 1964

Stanford University Program, Pediatrics

Fellowship 1965

Stanford University Program, Pediatrics

Fellowship 1967

National Institutes of Health Clinical Center Program, Pediatrics

Outstanding Physician Clinician in Diabetes 2001

American Diabetes Association

Lifetime Achievement Award 2003

Juvenile Diabetes Research Foundation

For Patients:
Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied
For Referring Providers:
Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Development of strategies aimed at prevention of the eye and kidney complications of type I diabetes, based upon controlling HbA1c levels and blood pressure levels. His first longitudinal report of HbA1c levels in relation to diabetic eye and kidney complications was reported in JAMA in 1989. The development of new insulins and their use in children: he was the first to report the use of postprandial Humalog in toddlers and on the use of Humalog in the phone management of ketonuria. Ketoacidosis has been of interest for many years (Pediatrics in Review, 1990). A report is now in progress relating to the prevention of severe DKA and cerebral edema. Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied

PRODWEBSERVER1